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Michael Kosteljanetz4 and Hans Skovgaard Poulsen1*Abstract
Background: Although implementation of temozolomide (TMZ) as a part of primary therapy for glioblastoma
multiforme (GBM) has resulted in improved patient survival, the disease is still incurable. Previous studies have
correlated various parameters to survival, although no single parameter has yet been identified. More studies and
new approaches to identify the best and worst performing patients are therefore in great demand.
Methods: This study examined 225 consecutive, non-selected GBM patients with performance status (PS) 0–2
receiving postoperative radiotherapy with concomitant and adjuvant TMZ as primary therapy. At relapse, patients
with PS 0–2 were mostly treated by reoperation and/or combination with bevacizumab/irinotecan (BEV/IRI), while a
few received TMZ therapy if the recurrence-free period was >6 months.
Results: Median overall survival and time to progression were 14.3 and 8.0 months, respectively. Second-line
therapy indicated that reoperation and/or BEV/IRI increased patient survival compared with untreated patients and
that BEV/IRI was more effective than reoperation alone. Patient age, ECOG PS, and use of corticosteroid therapy
were significantly correlated with patient survival and disease progression on univariate analysis, whereas p53,
epidermal growth factor receptor, and O6-methylguanine-DNA methyltransferase expression (all detected by
immunohistochemistry), tumor size or multifocality, and extent of primary operation were not. A model based on
age, ECOG PS, and corticosteroids use was able to predict survival probability for an individual patient.
Conclusion: The survival of RT/TMZ-treated GBM patients can be predicted based on patient age, ECOG PS, and
corticosteroid therapy status.
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Glioblastoma multiforme (GBM) is the most common
adult primary brain tumor [1] and patients generally have a
dismal prognosis with a median survival of just 15 months
[2]. Newly diagnosed patients often undergo surgical
tumor resection and studies have shown that the extent of
surgical resection is correlated with increased median
survival duration [3,4]. Given that surgery as a single* Correspondence: hans.skovgaard.poulsen@regionh.dk
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distribution, and reproduction in any mediumtreatment is insufficient due to a diffuse infiltration by
tumor tissue into the brain, patients generally receive con-
comitant and adjuvant chemotherapy with temozolomide
(TMZ) in combination with radiotherapy (RT) [2,5]. TMZ
is an alkylating agent that induces cell death primarily
through the formation of O6-methylguanine DNA adducts,
resulting in DNA double-strand breaks [6]. The drug is
well tolerated with mostly mild to moderate adverse events
[7]. Preclinical studies have shown that TMZ sensitizes
GBM cells to RT [8,9], which might explain why the com-
bination is favorable. However, despite the EORTC-NCIC
trial originally showing a survival benefit in all patientstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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that nearly all patients experienced relapse and only 9.8%
survived 5 years after initial diagnosis [10].
The response to and survival following RT/TMZ therapy
has been correlated with several patient-specific variables.
The most frequently reported predictive variables include
patient age, performance status (PS), extent of surgical
resection, and expression of O6-methylguanine-DNA
methyltransferase (MGMT) [11-16], a DNA repair protein
inhibiting the effect of TMZ by reversing alkylation [17].
Predictive variables that have been less frequently reported
include tumor size [12], corticosteroid therapy [14], and
positivity for a number of overexpressed or mutated mole-
cules, including epidermal growth factor receptor (EGFR),
and p53 [18,19].
Although GBM tends to recur locally [20], repeat
surgery is only a treatment option for a limited number
of patients due to poor PS, large tumor volumes, and
involvement of critical brain areas [21]. As an alternative,
patients with relapsed tumors have received chemotherapy
or different kinds of molecular-targeted therapies [5].
Among the latter is bevacizumab (BEV), a humanized
monoclonal antibody targeting vascular endothelial growth
factor (VEGF). VEGF promotes proliferation, survival, and
migration of endothelial cells, and is expressed and released
mainly from tumor cells in response to pro-angiogenic
stimuli [22]. GBM is one of the most vascularized tumors
[23] and GBM tumors express high levels of angiogenic
factors including VEGF [24]. Various studies, both retro-
spective and prospective, have shown that BEV with or
without cytotoxic chemotherapy results in a substantive
response rate and improved 6-month progression-free
survival in GBM patients who have relapsed after previous
RT/TMZ treatment [25]. However, the effect of BEV on
overall survival (OS) has been somewhat modest, with
most studies reporting median OS values of <10 months
after initiation of BEV therapy [25].
To maximize patient survival and avoid unnecessary
treatments, prognostic parameters must be taken into
account when deciding which treatment modality is
most appropriate for the individual patient. Recursive
partitioning analysis (RPA) is a tool developed in the
early 1990s with which it is possible to categorize brain
cancer patients into subgroups with different median
survival according to a number of clinical and therapeutic
parameters [26]. GBM-specific adaptations have been
developed [27,28] and research has shown prognostic
significance of the classification for GBM patients receiving
RT with or without TMZ [27]. However, the RPA classifica-
tion is somewhat crude as a prognostic tool for therapeutic
decision making and is more useful for the stratification of
patients in clinical trials. As an alternative, more precise
prognostic calculators have been developed for GBM
patients receiving RT/TMZ [14,29]. However, as thenumber of studies of prognostic calculators in GBM pa-
tients is limited, the approach needs further investigation.
In this study we analyzed clinical and molecular data
retrospectively in a cohort of 225 newly diagnosed con-
secutive GBM patients treated with RT/TMZ as primary
therapy. Parameters identified to correlate to tumor pro-
gression and patient survival were assembled in a prognos-
tic model able to predict patient survival. In addition, the
effects of repeat surgery, BEV plus irinotecan (IRI) therapy,
and the combination of both therapeutic modalities were
compared for the treatment of relapsed tumors.
Methods
This study was performed according to the Declaration
of Helsinki and Danish legislation. Permissions were given
from the Danish Data Protection Agency (2006-41-6979)
and the ethical committee for the Capital Region of
Denmark (H-C-2008-095).
Patients
This study included a consecutive series of 225 patients
with newly diagnosed GBM (WHO grade IV) recruited
from 2005 to 2010 who were not selected other than
having ECOG PS 0–2. There were 80 women and 145 men
with a median age of 59.2 years (range, 22.6–75.4 years). Of
these, 198 patients presented with a single tumor, while 26
patients had multifocal disease (data missing, n = 1). ECOG
PS was 0 (n = 132), 1 (n = 66), or 2 (n = 19) [data missing,
n = 8]. Patient demographics are shown in Table 1.
Treatments
Patients underwent surgery, taking either a tumor biopsy
(n = 29) or resulting in partial (n = 104) or complete tumor
resection (n = 89) prior to additional therapy (data missing,
n = 3). The extent of surgical radicality was based on the
impression of the surgeon.
Patients received 6 weeks of concomitant RT/TMZ
therapy as primary treatment. They received TMZ 75 mg/
m2/day plus RT at a dose of 60 Gy to the planning target
volume in 30 fractions with 5 fractions/week delivered by a
megavoltage linear accelerator. Cerebral CT was performed
with 3-mm slices and fused with baseline MRI for
treatment planning. Treatment planning was performed
three-dimensionally using Eclipse™ treatment planning
system (Varian Medical Systems, Palo Alto, CA) and
volumes of interest were defined in agreement with
International Commission on Radiation Units & Measure-
ments Reports 50 and 62. The gross tumor volume (GTV)
was defined as the contrast-enhanced tumor on post-
contrast T1 image and/or the non-enhancing area on the
T2 image on the baseline MRI scan. The clinical target
volume (CTV) as defined as the GTV + 2 cm margin,
except for bony structures. Meningeal structures were
considered anatomic barriers to tumor spread, if appropriate
Table 1 Patient demographics, therapy, and response
(N = 225)













Extent of tumor resection, n (%)
Biopsy 29 (12.9)
Partial resection 104 (46.2)
Gross total resection 89 (39.6)
Missing 3 (1.3)
























Follow-up duration (months), median (range) 60 (23–92)
Table 1 Patient demographics, therapy, and response
(N = 225) (Continued)






Abbreviations: CR complete response, PD progressive disease, PR partial
response, RT radiotherapy, SD stable disease, TMZ temozolomide.
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The internal target volume was identical to the CTV.
No variations in size, shape or position of CTV in relation
to anatomical reference structures were considered. Plan-
ning target volume was defined as the CTV + 0.5 cm
margin for patient setup inconsistencies. Tolerance doses
for organs at risk were as described by Emami et al. [30].
During this treatment, patients were also given antibiotic
prophylaxis with 400 mg sulfamethoxazole/80 mg tri-
methoprim 3 times/week. In addition, a number of patients
received corticosteroid therapy to relieve neurological
symptoms: 165 patients (73%) received corticosteroid
therapy at the initiation of RT/TMZ therapy.
Four weeks after completion of initial therapy, patients
were given up to six courses of adjuvant TMZ therapy,
with one course defined as TMZ for 5 days followed by
23 days without therapy. The initial course was given at
a dose of 150 mg/m2/day and the remaining courses at a
dose of 200 mg/m2/day. The dose was adjusted based on
relevant blood tests. The number of adjuvant TMZ
therapy courses given is summarized in Table 1.
As therapy for recurrent tumors, patients who maintained
ECOG PS 0–2 were initially considered for secondary
surgery to remove as much tumor as possible. These
patients were thereafter considered for secondary therapy
with TMZ 150–200 mg/m2/day if they had already
received 6 courses of adjuvant TMZ and thereafter had a
recurrence-free period ≥6 months. The courses consisted
of 5 days TMZ therapy followed by 23 days without
therapy. From 2006, regardless of adjuvant TMZ therapy
and extent of recurrence-free period, the patients were
additionally considered for second-line therapy with BEV
10 mg/kg every 2 weeks and irinotecan (IRI), as previously
described [31]. In total, 74 patients underwent secondary
surgery, 12 received second-line therapy with TMZ,
and 85 received second-line therapy with BEV/IRI.
Characterization of the therapy is detailed in Table 1.
Clinical evaluation
At treatment initiation, a full medical history was deter-
mined and patients were examined for baseline physical
and neurological status. In addition, ECOG PS [32] was
Figure 1 Examples of IHC stainings. p53, EGFR, and MGMT
expression by IHC scored semiquantitatively on the scale: <10%,
10–25%, 25–50%, and >50% cells stained positive. Representative
photomicrographs (200× magnification) are given for GBM tissue
with <10% (I, III, V) and >50% (II, IV, VI) positive cells. Cells staining
positive for MGMT in V represent macrophages and endothelial cells
of vessels, while it is tumor cells that stains positive for p53 in I.
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chemistry and urinalysis) were performed, and MRI scans
were undertaken to evaluate tumor size and location.
The median duration of observation from the day
patients first received therapy to the project cut-off day
(22 October 2012) was 60 months (range, 23–92 months).
In this period contrast and non-contrast MRI scans were
repeated after 2, 5, and 6 courses of adjuvant TMZ.
Patients’ neurological and clinical performance, together
with corticosteroid treatment, was recorded at these
time points. All patients were thereafter followed every
3 months until death or study cut-off date using the same
procedures. Safety was determined using NCI-CTCAE,
version 3.0, criteria [33].
Histological and immunohistochemical evaluation
Evaluations were made on formalin-fixed, paraffin-
embedded tissue. Tumor tissue was classified and graded as
GBM according to WHO 2007 guidelines. Diagnosis was
based on conventional histological and immunohistochemi-
cal (IHC) procedures, including staining with hematoxylin
and eosin, glial fibrillary acidic protein (GFAP), p53, EGFR,
and MGMT. For IHC, sections were pre-treated in a
microwave oven with a Tris/ethylene glycol tetra-acetic
acid buffer (pH 9.0) and immunostained on a DAKO
Cytomation autostainer using murine monoclonal antihu-
man antibodies against GFAP (Z 0334, 1:6400), p53 (M
7001, 1:800), EGFR (M 7239, 1:200) [all from DAKO,
Glostrup, Denmark] and MGMT (MAB16200, 1:200,
Millipore, USA). The p53, EGFR, and MGMT IHC reac-
tions were semiquantitatively evaluated according to the
number of cells stained: <10%, 10–25%, 26–50%, and >50%.
Staining examples are shown in Figure 1. For statistical
analysis, expression evaluated as <10% was considered
negative, while ≥10% was considered positive.
Study endpoints
Study endpoints were time to progression (TTP), OS,
OS from recurrence, response at 3 and 6 months, and
best response. TTP was defined as the time from the
start of RT/TMZ treatment to radiological or clinical
progression. OS was defined as the time from start of
RT/TMZ treatment until death from any cause, while
OS from recurrence was defined as the time from tumor
relapse until death from any cause.
Response was evaluated 3 and 6 months after completion
of RT. Response evaluation was based on MacDonald
criteria [34], considering MRI measurements of contrast-
enhancing tumor size and recording of the largest cross-
sectional area of the tumor, patient neurological status,
and corticosteroid dose. Complete response (CR) was
defined as complete disappearance of measurable disease
by MRI, partial response (PR) as >50% reduction of MRI
contrast enhancing tumor, and progressive disease (PD)as >25% increase in area of contrast enhancement. Patients
with CR or PR also had to be taking the same or decreased
corticosteroid dose and have stable or improved neuro-
logical findings. Patients, by definition, had stable disease
(SD) if the criteria for CR, PR, or PD were not met and no
clinical progression was observed.
For each patient, responses after 3 and 6 months were
compared and a ‘best response’ determined, defined as the
maximum achieved response registered for the patient in
the observation period.
Statistical considerations
Factors that were analyzed as potential markers of prognos-
tic significance included: age, gender, ECOG PS, extent of
resection, tumor location, tumor size, previous corticoster-
oid therapy, and tumor EGFR, p53, and MGMT expression.
Univariate and multivariate analyses of response data were
performed using logistic regression analysis modeling the
probability of MacDonald response at 3 and 6 months as
well as the best response. Estimates of survival probabilities
for OS (primary endpoint) and TTP (secondary endpoint)
were performed by the Kaplan-Meier method. Univariate
and multivariate analyses of OS and TTP for the chosen ex-
planatory variables were performed using the Cox propor-
tional hazards regression model. Analysis of time-dependent
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well as the time-dependent Cox regression model.
The final model was chosen using a backwards selection
procedure, the entry level was 5%. The analysis was
repeated removing the least significant covariate in order to
use all available data, in particular the molecular markers
were only done for a subset of patients. Model assessment
was done using Schoenfeld and martingale residuals. The
overall concordance index (C-index) was used as a measure
of discrimination [35,36] and calculated in accordance to
previously published guidelines [37]. In addition, a 5 fold
cross validation was done to evaluate the model.
P values < .05 were considered significant. Calculations
have been performed using IBM SPSS Statistics (v19.0,
IBM Denmark, Kgs. Lyngby, Denmark) and SAS (v9.2,
SAS Institute, Cary, NC) software.
Results
Significant factors affecting outcome from first-line
RT/TMZ
As shown in Table 1, best responses to first-line RT/TMZ
among evaluable patients were: CR (n = 6; 2.9%); PR
(n = 17; 8.1%); SD (n = 93; 44.3%); and PD (n = 94; 44.8%).
Data were missing for 15 patients, who were therefore not
evaluated. The effects of clinical and molecular variables
on best response and response at 3 and 6 months on
univariate analysis are summarized in Tables 2 and 3,Table 2 Univariate analysis of correlation of clinical variables
Covariate OS TTP
(HR) [95% CI] (HR) [95% CI]
Operation
Gross total vs. biopsy 0.76 (0.49–1.17) 0.74 (0.48–1.16)
Partial vs. biopsy 0.98 (0.64–1.50) 0.86 (0.56–1.32)
P = .22 P = .37
Age (per 10-year increase) 1.36 (1.17–1.58) 1.17 (1.01–1.36)
P < .0001 P = .034
Gender (female vs. male) 1.11 (0.83–1.47) 1.07 (0.8–1.44)
P = .47 P = .64
Multifocal vs. single lesion 1.23 (0.80–1.88) 1.26 (0.82–1.93)
P = .34 P = .29
Tumor size (2-fold increase) 1.00 (0.88–1.14) 0.98 (0.87–1.11)
P = .97 P = .74
Corticosteroid therapy (yes vs. no) 2.13 (1.49–2.86) 1.41 (1.02–1.92)
P < .0001 P = .036
ECOG performance status
1 vs. 0 1.42 (1.04–1.94) 1.33 (0.97–1.84)
2 vs. 0 2.31 (1.40–3.82) 1.70 (1.03–2.80)
P = .0015 P = .046
Abbreviations: CI confidence interval, HR hazard ratio, NA not analyzed, OR odds ratirespectively. The only clinical variable with a significant
effect on response was patient age, for which a 10-year
increase resulted in a reduction of the best response
(P = .045). None of the other clinical factors examined
had a statistically significant impact on patient best
response or response at 3 and 6 months. EGFR, p53,
and MGMT expression were examined as potential
molecular markers for response (Table 3). Because of
missing data, analyses were only available for subsets
of patients: 145 of 199 patients presented EGFR-
positive tumors; 105 of 202 patients presented p53-
positive tumors; and 65 of 163 patients presented
MGMT-positive tumors. There was no significant correl-
ation between EGFR and MGMT expression and best re-
sponse or response at 3 and 6 months. The odds ratio for
response at 3 months among patients with p53-positive
tumors was significantly (P = .043) higher as compared to
those with p53-negative tumors. Although not significant,
this tendency was also seen for the best response
(P = .053) but not for response at 6 months (P = .21).
All 225 patients had TTP data, of whom 199 had
disease progression. Median TTP was 8.0 months (95%
CI, 6.7–9.0 months) with progression free survival of 61%
(95% CI, 54–67%) at 6 months and 28% (95% CI, 22–34%)
at 12 months (Figure 2). Increased patient age (P = .034),
higher ECOG PS score (P = .046), and use of corticosteroid









(HR) [95% CI] (OR) [95% CI] (OR) [95% CI] (OR) [95% CI]
0.81 (0.51–1.27) 4.33 (0.54–35) 1.88 (0.21–16.9) 4.00 (0.49–32)
1.05 (0.68–1.65) 1.37 (0.15–12.2) 0.86 (0.09–8.22) 2.13 (0.25–17)
P = .23 P = .07 P = .35 P = .24
1.36 (1.16–1.60) 0.66 (0.43–1.01) 0.76 (0.46–1.23) 0.66 (0.44–0.99)
P = .0001 P = .056 P = .26 P = .045
1.01 (0.75–1.37) 1.48 (0.59–3.75) 1.31 (0.49–3.53) 1.68 (0.70–4.02)
P = .94 P = .41 P = .29 P = .24
1.16 (0.74–1.81) NA NA NA
P = .52
1.03 (0.90–1.19) 1.41 (0.87–2.29) 1.56 (0.95–2.57) 1.39 (0.89–2.16)
P = .64 P = .16 P = .08 P = .15
2.17 (1.54–3.03) 0.44 (0.17–1.11) 0.78 (0.28–2.17) 0.57 (0.23–1.39)
P < .0001 P = .08 P = .63 P = .22
1.58 (1.13–2.20) 0.26 (0.06–1.16) 0.22 (0.05–0.97) 0.22(0.05–0.97)
2.34 (1.39–3.93) 0.88 (0.18–4.19) 0.71 (0.15–3.32) 0.71(0.15–3.35)
P = .0007 P = .21 P = .13 P = .13
o, OS overall survival, TTP time to disease progression.










(HR) [95% CI] (HR) [95% CI] (HR) [95% CI] (OR) [95% CI] (OR) [95% CI] (OR) [95% CI]
EGFR
Positive (n = 145) 1.05 (0.77-1.43) 0.82 (0.61-1.12) 1.02 (0.75-1.41) 0.64 (0.22-1.86) 0.64 (0.46-4.15) 1.06 (0.22-1.91)
P = .75 P = .21 P = .89 P = .41 P = .96 P = .43
Negative (n = 54)
Missing (n = 26)
p53
Positive (n = 105) 0.76 (0.55-1.05) 0.92 (0.66-1.27) 0.73 (0.52-1.03) 3.01 (1.04-8.7) 2.04 (0.68-6.1) 2.64 (0.99-7.1)
P = 0.10 P = .60 P = .071 P = .043 P = .21 P = .053
Negative (n = 97)
Missing (n = 23)
MGMT
Positive (n = 65) 0.97 (0.64-1.48) 0.90 (0.59-1.36) 1.42 (0.91-2.19) 1.36 (0.35-5.34) 1.02 (0.25-4.18) 1.78 (0.52-6.13)
P = 0.89 P = 0.61 P = .12 P = 0.66 P = .98 P = .36
Negative (n = 98)
Missing (n = 62)
Positive and negative expression are defined by ≥10% and <10% of cells, respectively, stained on immunohistochemical analysis. Abbreviations: CI confidence
interval, HR hazard ratio, OR odds ratio, OS overall survival, TTP time to disease progression.
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examined clinical or molecular variables had a significant
impact on TTP (Tables 2 and 3).
All 225 patients had OS data, of whom 204 (90.7%)
died during the observation period. Median OS was
14.3 months (95% CI, 13.0–15.8 months) with an OS rate
of 27.1% (95% CI, 21–33%) at 2 years and 13.9% (95% CI,
9.5–19.0%) at 3 years (Figure 2). Median OS from tumor
recurrence was 5.9 months (95% CI, 5.0–6.9 months).
Increased patient age (P < .0001), higher ECOG PS score
(P = .0015), and use of corticosteroid therapy at RT/TMZ
initiation (P < .0001) had a significant negative impact onFigure 2 Kaplan-Meier plots showing TTP and OS for the patient pop
Numbers for patients at risk at selected times are shown in addition to theOS (Table 2). Increased patient age (P = .0001), higher
ECOG PS score (P = .0007), and use of corticosteroid
therapy at RT/TMZ initiation (P < .0001) also showed a
significant negative correlation with decreased OS from
disease recurrence. None of the other clinical covariates
were significantly correlated with OS or OS from disease
recurrence. None of the molecular markers (EGFR, p53,
and MGMT) were significantly correlated with patient
survival (Table 3). There was a non-significant trend
for longer OS (P = .10) and OS from disease recurrence
(P = .071) among patients with p53-positive tumors as
compared to those with p53-negative tumors.ulation. The curves are based on data from all 225 examined patients.
total number of events (deaths for OS and progression for TTP).
Michaelsen et al. BMC Cancer 2013, 13:402 Page 7 of 11
http://www.biomedcentral.com/1471-2407/13/402Reoperation and second-line BEV/IRI therapy for
relapsed-tumors improve survival
A total of 199 patients presented relapse. Most of these
patients underwent reoperation of the tumor (n = 31;
15.6%), received BEV/IRI therapy (n = 42; 21.1%), or
had a combination of both modalities (n = 43; 21.6%)
for recurrent disease. In addition, 12 patients received
second-line TMZ therapy as they had received 6 courses of
adjuvant TMZ therapy and did not have disease recurrence
for >6 months: due to the limited number of patients
receiving this therapeutic option, this treatment was
excluded when analyzing the effect of the different
second-line treatments on survival. Compared to patients
who received no second-line therapy, there was a signifi-
cant OS increase in those who underwent reoperation
(hazard ratio (HR) = 0.39; 95% CI, 0.25–0.60) or received
BEV/IRI therapy (HR = 0.23; 95% CI, 0.15–0.34) as single
treatments. When comparing OS for patients who received
BEV/IRI as single second-line therapy with those who
received a combination of reoperation plus second-line
BEV/IRI therapy, there was no significant beneficial effect,
although there was a tendency for better survival among
those who received the combination (HR = 0.87; 95% CI,
0.46– 1.37). In contrast, when the reoperation-BEV/IRI
combination was compared to reoperation alone, there
was a significant increase in survival (HR = 0.51; 95%
CI, 0.31–0.83).
A prognostic model can predict survival of GBM patients
receiving RT/TMZ
Multivariable analyses of TTP and OS were done including
the covariates described in Tables 2 and 3.
Multivariable analysis of the secondary endpoint, TTP,
yielded a final model only including corticosteroid therapy
(yes vs no, HR = 1.41 (95% CI, 1.02-1.92), p = 0.036). The
p-values to include ECOG PS and age in the final model
were 0.12 and 0.21 respectively. The p-values to include
the remaining covariates were all >0.14.
A final model was selected for the primary endpoint
OS, the following covariates were statistically significant
ECOG PS (PS 1 vs 0, HR = 1.22 (95% CI, 0.89-1.68),
PS 2 vs 0, HR = 2.06 (95% CI, 1.25-3.42), p = 0.015),
corticosteroid therapy (yes vs no, HR = 2.06 (95% CI,
1.47-2.87), p < 0.0001) and age (per 10 years, HR = 1.31
(95% CI, 1.11-1.54), p = 0.001). P values to include the
excluded covariates in the final model were >0.17 (P53,
p = 0.57; MGMT, p = 0.24; EGFR, p = 0.45; tumor size,
p = 0.51; operation, p = 0.84; multifocal vs. single lesion,
p = 0.17). Significant interactions could not be demon-
strated suggesting an additive effect of these covariates.
Model assessment was found to adequate. The overall
concordance index (C-index) [35-37] for the final model
was 0.82 (95% CI, 0.71–0.92), which can be interpreted
as the probability of concordance between predictedand observed survival, thereby demonstrating a substantial
discrimination for this model. The results of the five-fold
internal cross validation supported the chosen model
validating the model in the 5 test sets (C-indices > 0.80).
Based on estimated regression coefficients, patient
survival chances at 6, 12, 18, and 24 months after diagno-
sis were calculated for various levels of each of the three
covariates (Table 4). For example, the survival probability
for a 40-year-old patient with ECOG PS 0 receiving no
corticosteroid therapy was 97%, 86%, 73%, and 64% at 6,
12, 18 and 24 months, respectively, following diagnosis.
A much lower survival probability is exemplified for a
80-year-old patient with ECOG PS 2 receiving corticoste-
roids: 67%, 15%, 2%, and 0% at 6, 12, 18, and 24 months,
respectively from diagnosis. It can also be seen that a
change in several variables at the same time can have a
major negative impact on the survival probability for
the individual patient, while a change in only one of the
three factors had a relatively minor impact on the survival
probability. This is exemplified by a survival probability of
24% at 12 months after diagnosis for a 70-year-old patient
with ECOG PS 2 receiving corticosteroid therapy compared
to 67% for a 50-year-old patient with ECOG PS 0 receiving
corticosteroid therapy, and 82% for a 50-year-old patient
with ECOG PS 0 not receiving corticosteroid therapy. It
is noteworthy that a 20-year increase of patient age has
a negative effect on survival probability that is similar to
that seen for an increase in ECOG PS from 0 to 2 or
corticosteroid therapy vs. no therapy.
Discussion
In this study, we examined a cohort of newly diagnosed
GBM patients treated with RT plus concomitant and
adjuvant TMZ as primary therapy. We observed a median
OS of 14.3 months and a median TTP of 8.0 months
(Figure 2), which is very similar to values found in the
EORTC-NCIC trial (14.6 and 6.9 months respectively)
[2]. Based on this and the fact that the examined patients
were consecutive and not selected, we conclude that the
patients included are good representatives for the general
population affected with GBM.
As treatment for recurrent disease, we found that both
BEV/IRI therapy and reoperation resulted in significantly
increased OS compared to untreated patients, which is
in line with other studies [25,38]. In addition, our results
indicate that BEV/IRI therapy is more effective than
reoperation as second-line therapy for the majority of
patients with recurrent GBM tumors and that the therapy
should be given in combination with reoperation when
possible. However, as the second-line treatments were
based on individual evaluation of patient health status and
not on a randomized trial, this could result from the fact
that mainly the best performing patients received the
reoperation and BEV/IRI combination. Randomized clinical
Table 4 Estimated survival probabilities from diagnosis
















0 No 40 97 86 73 64
45 96 84 70 60
50 96 82 66 56
55 95 80 62 51
60 95 77 58 46
65 94 74 54 41
70 93 71 49 36
75 92 68 44 32
80 91 64 39 27
Yes 40 94 73 52 40
45 93 70 48 35
50 92 67 43 30
55 91 63 38 25
60 89 59 33 21
65 88 54 28 16
70 86 50 23 13
75 84 45 19 9
80 82 40 15 7
1 No 40 96 83 68 58
45 96 81 64 53
50 95 79 60 49
55 94 76 56 44
60 93 73 52 39
65 93 70 47 34
70 91 66 42 29
75 90 62 37 24
80 89 58 32 20
Yes 40 92 68 45 32
45 91 65 40 28
50 90 61 35 23
55 89 57 30 18
60 87 52 26 14
65 85 47 21 11
70 83 43 17 8
75 81 38 13 5
80 79 33 10 4
2 No 40 94 73 52 40
45 93 70 47 35
50 92 67 43 30
55 90 63 38 25
60 89 59 33 20
Table 4 Estimated survival probabilities from diagnosis
depending on patient ECOG PS, corticosteroid therapy
use and age (Continued)
65 88 54 28 16
70 86 50 23 12
75 84 45 19 9
80 82 40 15 7
Yes 40 87 53 26 15
45 85 48 22 11
50 84 43 17 8
55 81 38 13 6
60 79 33 10 4
65 76 28 7 2
70 73 24 5 1
75 70 19 3 1
80 67 15 2 0
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these two different second-line treatments.
Although RT/TMZ improves survival as compared to
patients receiving RT alone, it only results in long-term
survival (>2 years) for <30% of patients [10]. Much effort
has been devoted to finding parameters that correlate with
response to and survival following RT/TMZ therapy. Using
univariate analysis in the present study, we found that
three clinical markers (age, ECOG PS, and corticosteroid
therapy at treatment initiation) had a significant impact on
survival following therapy (Table 2). All three variables
have been previously reported to affect survival. However,
while an analysis of the EORTC-NCIC trial data was able
to find an impact of all three variables [14], studies on
other patient groups only saw a significant effect for one
of these markers [12,16].
Contrary to our expatiations, we were not able to find
any significance from the extent of primary operation in
our study (Table 2), although several other studies have
shown a significant effect for this variable on the response
and survival of GBM patients treated with RT/TMZ
[13-15,39]. As in other studies with similar negative
results [12,40], we expect that the non-significant result is
caused by incorrect assessment of surgical radicality,
which in this study was estimated based on surgeons’
impression of tumor remaining in the resection area.
Supporting this is the significant effect observed in our
study for second-line reoperation, which was performed
by a more experienced team of surgeons at our institution.
Our results underline the importance of standardizing
the evaluation process, in which the use of early (within
72 hours of surgery) MRI scans could be an important
tool, a method used in several studies finding an effect
of primary surgery [13,39].
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EGFR and p53 in the response of GBM to TMZ. Studies
on GBM cells couple signaling from the EGFR receptor
to reduced sensitivity to chemotherapeutic agents that, like
TMZ, have alkylating activity [41,42], while p53 inactiva-
tion in GBM cells results in increased TMZ sensitivity
[43,44]. However, in line with previous studies examining
the prognostic value of EGFR [13,18,40,45] in TMZ-treated
GBM patients, we were unable to find a significant correl-
ation between this molecule and patient response or
survival (Table 3). We found a significantly increased
response rate in patients who had p53-positive tumors
compared to those with p53-negative tumors, although
we were unable to find a significant effect on OS and TTP.
This adds to the conflicting picture existing for this
molecule, for which both significant and non-significant
results exist regarding its effect on response and survival
[13,18,40,45]. Overall, these results indicate that EGFR
and p53, despite their involvement in GBM tumor devel-
opment and growth, not are main players in the response
of GBM tumors to TMZ. However, improved assay
techniques and consideration of tumor heterogeneity
are necessary to confirm this.
Many studies have shown a significant correlation
between lack of MGMT expression and survival of
TMZ-treated GBM patients [11,13,14]. However, the
detection method varies from direct detection of the
MGMT protein to indirect detection of the methyla-
tion status of the MGMT promoter as a marker for its
expression [46]. In line with previous studies [12,13],
we were unable to show a significant correlation be-
tween MGMT status and outcome following RT/TMZ
therapy when detecting MGMT at the protein level
using IHC. This, combined with an analysis which
found that MGMT protein expression does not correl-
ate with the promoter methylation status of MGMT
[47], indicates that IHC is not a reliable technique for
MGMT detection for prediction of patient response to
TMZ.
Emerging results show that GBM tumors can be
subclassified into different groups based on their molecular
expression patterns and that these subclasses correlate
to variations in patient survival [48,49]. This observation
indicates that individualized therapy could be a way to
increase the survival of GBM patients.
Research conducted on parameters that are able to
predict response and survival following TMZ therapy
has mostly centered on single markers. This has resulted
in the identification of a number of both clinical and
molecular parameters [11-13,16], but none of these have
been able to give an accurate prediction of RT/TMZ
therapy outcome for the individual patient. As a result,
no markers have been implemented to segregate patients
into responders and non-responders for RT/TMZ therapy,although the combination has been given as standard
therapy for GBM patients since 2005. That an approach
taking several markers into account simultaneously is
beneficial is indicated by the ability of the RPA classifi-
cation system to subgroup RT/TMZ-treated patients
according to survival [27] and by studies that are able
to increase the predictive effect using multigene [50] or
multimethylation [51] profiles as compared to the use of
single variables.
Based on these facts, we assembled a model to predict
patient survival using the individual variables that we
had identified as significant for survival (age, ECOG PS
and corticosteroid therapy at treatment initiation). The
model, which was developed using cox modelling, is able
to calculate the probability for a given patient receiving
the described therapy to be alive at a given time and can be
used to identify patients with the best and worst survival
chances (Table 4). Another approach could be recursive
partitioning, thereby making a decision tree model as used
in the RPA classification system. However, as discussed
previously [14,28], this approach groups the variables into
only a few categories and cannot predict the survival for
the individual patient.
Furthermore, our model contributes to the debate on
which therapeutic option should be preferred for eld-
erly patients [52]. Both RT [53] and TMZ [54] have
been proven to result in survival benefit for elderly
GBM patients. However, due to the general belief that
elderly patients do not tolerate concomitant chemo-
radiotherapy as well as younger patients in combin-
ation with the observation of a negative correlation
between patient age and the survival following RT/TMZ
therapy [14], this combination is not standard in elderly
patients. Our results indicate that age alone should not
disqualify patients from concomitant RT/TMZ therapy,
but that ECOG PS and use of corticosteroid therapy
should be taken into account for making any therapeutic
decisions. This conclusion supports several studies
which have found that RT/TMZ therapy is effective in
elderly GBM patients presenting with good prognostic
factors [15,55].
A few other studies have constructed prognostic models
for GBM patients. One model established from patients
receiving RT/TMZ as primary treatment in the EORTC-
NCIC trials includes age, PS, MGMT status, extent of
resection, and mental state [14]. Another model based on
GBM patients receiving RT/TMZ therapy for recurrent
disease includes PS, corticosteroid therapy, number of
lesions, and lesion size [29]. As PS is the only consistent
factor in all three studies, additional research is needed.
Nonetheless, the described prognostic models have the
potential to be valuable tools for clinicians when deciding
which therapeutic modality is the best for the individual
GBM patients.
Michaelsen et al. BMC Cancer 2013, 13:402 Page 10 of 11
http://www.biomedcentral.com/1471-2407/13/402Conclusions
This study demonstrates a significant impact of patient
age, ECOG PS and status of corticosteroid therapy on
TTP and OS for GBM patients treated with RT/TMZ as
primary therapy and re-operation or BEV/IRI as secondary
therapy. Further by assembling these variables in a model
the survival chances at different time-points from diagnosis
can be predicted for GBM patients receiving the described
therapy.
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